SPRINT: AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE STEP-UP VS TOP-DOWN TREATMENT ALGORITHMS IN MODERATE TO SEVERE ULCERATIVE COLITIS SPRINT: UN ESTUDIO ABIERTO, MULTICENTRICO PARA EVALUAR LOS ALGORITMOS DE TRATAMIENTO STEP-UP VERSUS TOP-DOWN EN LA COLITIS ULCEROSA DE MODERADA A SEVERA.
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms SPRINT
- 08 Mar 2024 This study has been discontinued in Italy, according to European Clinical Trials Database record.
- 17 Aug 2021 New trial record